To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:7 Number:611 ISSN#:2564-2537
ACE Report #5096
Ace Report Cover Tumour

Ewing sarcoma: Similar survival rates with intensified dose regimen of VDC/IE

How to Cite

OrthoEvidence. Ewing sarcoma: Similar survival rates with intensified dose regimen of VDC/IE. ACE Report. 2013;2(7):611. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study

J Clin Oncol. 2009 May 20;27(15):2536-41. doi: 10.1200/JCO.2008.19.1478. Epub 2009 Apr 6

Contributing Authors:
L Granowetter R Womer M Devidas M Krailo C Wang M Bernstein N Marina P Leavey M Gebhardt J Healey RC Shamberger A Goorin J Miser J Meyer CA Arndt S Sailer K Marcus E Perlman P Dickman HE Grier

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


478 patients under the age of 30, diagnosed with non-metastatic ESFT (or the Ewing sarcoma family of tumours), were randomized to either a standard or intensified dose regimen of vincristine, doxorubicin, and cyclophosphamide (VDC) along with ifosfamide and etoposide (IE) to assess the 5-year event-free and overall survival rates between groups. Results indicated that there was no significant diff...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.